Our news

New generation preparations – effective prevention and recovery from viral diseases

The world is changing, the viruses are evolving and the new environment of biosphere requires the new approach to the development of the drugs for the prevention and regeneration after viral diseases. It is no longer enough to use traditional medicines and drugs that can be sold in great numbers in every pharmacy.

In the framework of collaboration with WHO, AVA Pharmaceuticals (Pvt) Ltd company began supplying generic drugs for HIV, hepatitis B and C treatment to different countries of South America

Under the patronage of the World Health Organization, AVA Pharmaceuticals (Pvt) Ltd company began supplying generic drugs to different parts of South America as a part of the humanitarian mission. These generic drugs include some medications that are used for antiretroviral therapy to treat HIV, hepatitis B virus and hepatitis C virus infections.

AVA Pharmaceuticals (Pvt) Ltd company is conducting negotiations in order to obtain the right to release generic drugs, such as Edurant, Juluca and Odefsey

AVA Pharmaceuticals (Pvt) Ltd company announced the start of negotiations in order to obtain the patent right to manufacture generic drugs, such as Edurant, Juluca and Odefsey, their analogues do not exist today. These generic drugs include such medicinal agents as Avaril, Stoffi and Eveta.

AVA Pharmaceuticals (Pvt) Ltd company is conducting negotiations in order to obtain the right to manufacture a generic drug Keytruda

The pharmaceutical company AVA Pharmaceuticals (Pvt) Ltd announced the start of negotiation with the American company Merck & Co in order to obtain the right to develop and manufacture a generic drug Keytruda.

AVA Pharmaceuticals (Pvt) Ltd company issued an additional block of shares

The state pharmaceutical company AVA Pharmaceuticals (Pvt) Ltd announced the issue of the additional block of shares. The nominal value of a share is $2. The total amount of additional shares is about 20 million shares.